ThomasELoweMD

Oncology • Torrance, CA

Physician

Join to view full profile

Dr. Lowe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lowe's full profile

Already have an account?

Office
3285 Skypark Dr
Torrance, CA 90505
Phone+1 310-750-3300

Fax+1 310-379-3567
Is this information wrong?

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2005 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2005
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 2002 - 2003
David Geffen School of Medicine at UCLAClass of 2002

Certifications & Licensure

CA State Medical License 2004 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Friend of Nursing Award Providence Little Company of Mary Torrance Hospital, 2013
Physician Preference Award to Cancer Care Associates Healthcare Partners, 2011
Samuel Goldwyn Scholarship UCLA School of Medicine, 2002
American Society of Hematology Summer Research Award UCLA School of Medicine, 2001
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Join now to see all

Clinical Trials

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma Start of enrollment: 2012 Jun 14
Completed
Phase 1
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Start of enrollment: 2014 Jul 01
Terminated
Phase 3
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2014 Oct 23
Completed
Phase 2
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Start of enrollment: 2015 Jan 13
Completed
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) Start of enrollment: 2015 Jul 21
Active, not recruiting
Phase 3
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy Start of enrollment: 2015 Jun 01
Terminated
Phase 2
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Start of enrollment: 2015 Oct 15
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
John H Strickler, Antonio Cubillo, Jin-Tung Liang, Marc Matrana, Mark Kozloff, Thomas Lowe, Martha Blaney, Mohammad Sahtout, Louie Naumovski, Zev A Wainberg> ;Future Oncology. 2022 Sep 1
27 citations
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...
Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail, Thomas Lowe, Wolfgang Schütte, Hervé Lena, William E. Lawler, Fadi Braiteh, T...> ;Clinical Lung Cancer. 2017 Jan 1

Journal Articles

Male Breast Cancer 15 years After Allogeneic Bone Marrow Transplantation Including Total Body Irradiation for Recurrent Acute Lymphoblastic Leukemia: A Case Report and...
Lowe T, Luu T, Shen J, Bhatia S, Shibata S, Stein A, Somlo G, Onkologie, 2008
Intraperitoneal Chemotherapy in Ovarian Cancer. Future Medicine
Lowe T, Morgan RJ Jr, Future Medicine, 7/2007
Quality-of-Life Issues in the Management of Epithelial Ovarian Cancer
Lowe T, Ferrel B, Leong L, Current Treatment Options in Oncology - Springer, 1/1/2007
Second Malignancies after Allogeneic Hematopoietic Cell Transplantation
Lowe T, Bhatia S, Somlo G, Biology of Blood and Marrow Transplantation, 2007
Join now to see all

Books/Book Chapters

Breast surgical Techniques and Interdisciprinary Management
Chapter: Adjuvant Systemic Therapy in Breast Surgery
Lowe T, Somlo GEditors: Scott-Conner C and Dirbas F.Springer2011

Research History

Primary InvestigatorUCLA Translational Oncology Research International (TORI) Network. Including but not limited to trials in Non-Hodgkins Lymphoma, Lung Cancer, Bladder Cancer, Breast Cancer, Head and Neck Cancer2010 - Present
Primary AuthorBarriers and Delays in Breast cancer Treatment and the Treatment Implications. City of Hope. IRB# 061382006 - 2006
Primary AuthorPhase I/ll trial: Autologous Peripheral Blood Progenitor Cell Transplantation with VELCADE Maintenance as Treatment for Intermediate and Advanced-Stage Multiple Myeloma. Jonsson Comprehensive Cancer Center at UCLA. ClinicalTrials.gov Id: NCT00084747 Investigator Initiated. Millennium Pharmaceuticals2004 - 2004